IMV-2

IMV-2 is a preclinical bispecific antibody being developed by ImmuVia for the treatment of urothelial and gastrointestinal cancers. It is engineered using the company's proprietary Cancerlysin™ platform, which is designed to create bispecific antibodies that selectively target tumor cells while potentially engaging the immune system or inducing apoptosis. While the specific molecular targets for IMV-2 have not been publicly disclosed in the current pipeline documentation, the candidate is part of a broader portfolio of bispecific antibodies aimed at solid and hematological malignancies. The drug is currently in the preclinical stage of development.